Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been given an average rating of “Buy” by the six analysts that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have covered the stock in the last year is $21.00.

Separately, HC Wainwright started coverage on shares of Artiva Biotherapeutics in a research note on Monday, December 30th. They set a “buy” rating and a $20.00 target price for the company.

Hedge Funds Weigh In On Artiva Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new position in Artiva Biotherapeutics in the third quarter valued at $42,000. China Universal Asset Management Co. Ltd. acquired a new position in Artiva Biotherapeutics in the fourth quarter valued at $52,000. Wells Fargo & Company MN boosted its stake in Artiva Biotherapeutics by 64.0% in the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after acquiring an additional 3,361 shares in the last quarter. MetLife Investment Management LLC acquired a new position in Artiva Biotherapeutics in the third quarter valued at $135,000. Finally, JPMorgan Chase & Co. acquired a new position in Artiva Biotherapeutics in the third quarter valued at $166,000.

Artiva Biotherapeutics Stock Down 12.3 %

Artiva Biotherapeutics stock opened at $4.44 on Friday. Artiva Biotherapeutics has a twelve month low of $3.37 and a twelve month high of $17.31. The stock’s fifty day simple moving average is $5.27 and its 200-day simple moving average is $9.59.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.